Log In
Print this Print this

Rebif, interferon beta-1a

  Manage Alerts
Collapse Summary General Information
Company Merck KGaA
DescriptionNew formulation of Rebif recombinant interferon (IFN) beta-1a containing no human- or animal-derived serum
Molecular Target Type I interferon (IFN) receptor
Mechanism of ActionImmune modulation
Therapeutic ModalityBiologic: Protein
Latest Stage of DevelopmentMarketed
Standard IndicationMultiple sclerosis (MS)
Indication DetailsPrevent progression to clinically definite multiple sclerosis (MS); Treat clinically isolated syndrome (CIS); Treat patients who have experienced a single demyelinating event and are at risk of converting to multiple sclerosis (MS); Treat relapsing multiple sclerosis (MS); Treat relapsing-remitting multiple sclerosis (RRMS)
Regulatory Designation
PartnerPfizer Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today